The bradykinin (BK) B 2 receptor (B 2 R) is a well-known example of a G protein-coupled receptor submitted to a cycle of agonist-induced internalization and rapid recycling to the cell surface (Leeb -Lundberg et al., 2005 ) . The structural basis of the β -arrestin-mediated endocytosis is a phosphorylable domain present in the C-terminal tail of the receptor. Docking models of the peptide agonist BK and of some peptide B 2 R antagonists have also been proposed (Leeb -Lundberg et al., 2005 ) ; in these models, the C-terminus of the ligand plunges into the receptor central cavity, whereas the N-terminus interacts with an extracellular loop, presumably close to the extracellular fluid. Following our previous work on the N-terminal extension of BK with fluorophores or other drug-like moieties , we have explored the possibility of producing bifunctional, tagged B 2 R agonists that could bind to both an antibody and a receptor.
We have previously reported the endocytosis of immune complexes constructed at the surface of intact cells that express a B 2 R possessing a myc tag epitope at its N-terminus . The myc tag is a short sequence of 10 amino acids recognized by several commercial monoclonal antibodies, such as the 4A6 clone that we have previously exploited. This monoclonal does not inhibit [ 3 H]BK binding to myc-B 2 R (data not shown) and does not activate or antagonize myc-B 2 R (calcium mobilization assay, Bawolak et al. , 2011 ) consistent with the proposition that the B 2 R N-terminus is not critical for ligand binding (Leeb -Lundberg et al., 2005 ) . A variation of the myc-B 2 R-mediated endocytosis of the anti-myc monoclonal antibody 4A6 is schematically presented in Figure 1 A and experimentally tested in Figure 2 A. In the present case, the antibody is not revealed by a secondary antibody, as previously reported , but rather is conjugated with the fluorophore AlexaFluor-488. Intact and live cells were exposed first to a fluorophoreconjugated antibody and then, optionally, to the agonist BK. Cells that expressed the myc-B 2 R construct exhibited a labeling of their plasma membrane, but not other cells expressing a wild type B 2 R. BK stimulation very efficiently translocated the ~ 150 kDa murine immunoglobulin G bound to myc-B 2 R into endosomal structures ( Figure 2A) . As a control, both tagged and untagged receptors were revealed at the cell surface using the fluorescein-conjugated antagonist, fluorescein-5-thiocarbamoyl-(FTC-) B-9430 (Figure 2B ).
In the subsequent experiments, we have tested the idea of relocating the myc tag from the receptor to the peptide agonists of the B 2 R, thus making the transport of an antibody cargo by the wild type receptors via internalized bifunctional agonists possible ( Figure 1B) . The tagged agonists were designed to include the myc-epitope at the N-terminus, followed by the tripeptide spacer KGP from the amphibian peptide maximakinin, that exhibits an 8 -12-fold lesser potency relative to BK at mammalian B 2 R despite considerable extension Bawolak et al. , 2007 ) . The resulting peptides were rather large, 22-to 23-mers. They were pharmacologically evaluated using conventional assays for B 2 R ligands. In the human umbilical vein contractility assays, both myc-tagged peptides are agonists, with a 20-fold loss of potency for myc-KGP-BK but a larger one for myc-KGP-B-9972 (250-fold; Figure 3 A). Both peptides were antagonized by the non-peptide drug LF16-0687, which is consistent with their status as conventional B 2 R agonists ( Figure 3B and C). In the radioligand binding competition assay, based on the rabbit B 2 R conjugated with green fluorescent protein (B 2 R-GFP), the mycextended agonists are 196 -259 times less potent than the parent peptides ( Figure 3D ). ; sequences shown with one-letter codes for conventional amino acids; Hyp, trans -4-hydroxyproline; Igl, α -(2-indanyl)glycine; Oic, (3as,7as)-octahydroindol-2-yl-carbonyl; general methods for peptide production as in Gera et al. , 2012 ] . The tagged peptides may be transported via the wild-type (wt) B 2 R and detected with conjugated antibodies (AF488: AlexaFluor-488). Cells transiently expressing the wild-type rabbit B 2 R were treated with the fluorescent anti-myc antibody (added to the culture medium, with a final concentration of approximately 7 n m ) and, optionally, with a B 2 R agonist, incubated for 30 min and observed in epifluorescence (sample microphotographs, Figure 4 A; statistical analysis, Figure 4C ). When one of the myc-tagged agonists was added, fluorescent organelles were consistently observed in subsequently washed cells, but this reached statistical significance over autofluorescence only for myc-KGP-B-9972. The labeling was no stronger if myc-KGP-B-9972 was allowed to pre-react for 15 min with the antibody at room temperature before the mixture was introduced to the culture medium (data not shown). This endocytosis was blocked by pretreatment with the nonpeptide antagonist LF 16-0687. Importantly, BK was not capable of translocating the antibody when used at a concentration that induces massive B 2 R endocytosis, showing that intracellular labeling does not result from the endocytosis of a droplet of the fluorescent extracellular fluid (pinocytosis), but that a molecular combination is taking place in the extracellular fluid between the agonist myc-KGP-B-9972 and the antibody. Finally, this occurs even if the stoichiometry is not favorable, because there is a large molar excess of agonist molecules relative to the antibody. Figure 4B shows the same lots of cells that have taken up the fluorescein-conjugated agonist peptide FTC-B-9972 in the absence of the antibody; the same linear amplification of the signal has been Values are the means ± standard error of the mean of the number of determinations indicated by n or numbers in italics. Methods are the same as in Bawolak et al. (2007) ; anonymous use of human tissues was approved by a local ethics committee.
applied to this picture as to the other microphotographs in Figure 4 . The brighter cell labeling by the fluorescent agonist (1 mol of fluorophore taken up by 1 mol of endocytosed receptor) is consistent with the suboptimal stoichiometry of the fluorescent antibody uptake. Given the equal affinity of both tagged agonists for the rabbit B 2 R, the rigid backbone of myc-KGP-B-9972 in its agonist region may contribute to a more efficient recognition of the B 2 R when its epitope region is bound to the antibody, thus Figure 4A , general methods as in Gera et al. , 2011 ). limiting steric hindrance between the B 2 R and antibody. Adding the unconjugated anti-myc monoclonal antibody 4A6 (final concentration ~ 7 n m ) to myc-KGP-B-9972 did not increase the potency of the latter peptide in two pharmacological assays, the umbilical vein contractility and the competition assay of [ In cells that stably express B 2 R-GFP, myc-KGP-B-9972 induces a rapid and persistent endocytosis of the fluorescent receptor, as judged by the microscopic aspect of cells 30 min or 3 h after the cell treatment with the peptides ( Figure 5 ). As previously reported, BK is active in this respect within 30 min of application, but the fluorescent receptors are essentially recycled back to the cell surface 3 h after the application of the kinin. Thus, like its parent peptide (Bawolak et al. , 2007 ) , the myc-tagged agonist is resistant to endosomal inactivation. In other cells that coexpressed the wild-type B 2 R and cherry fluorescent protein-conjugated β -arrestin 1 , 3-h stimulation with myc-KGP-B-9972 combined with the fluorescent anti-myc antibody induced the endosomal condensation of the arrestin (red signal), and some of the labeled endosomes also contained the colocalized antibody (green signal, arrowheads), presumably in tetramolecular complexes that also contained the peptide agonist and the phosphorylated B 2 R ( Figure 5B ). Other cargo antibody molecules may have sorted toward late endosomes and lysosomes .
Despite its low receptor affinity, the bifunctional B 2 R agonist myc-KGP-B-9972 is resistant to endosomal inactivation and transports a large protein cargo into cells, supporting the prospects that functionally-active cargoes will enter cells in a pharmacologically-controlled manner. The transport of a very large, ~ 150 kDa antibody cargo by an activated G protein-coupled receptor, itself noticeable, may support various applications as one can vary the antibody conjugates in a modular manner. Some conjugated toxins, such as saporin and maytansinoids (Teicher and Doroshow , 2012 ) , resist endosomal hydrolases and kill tumor cells if allowed to enter the endocytic pathway even in very small quantities. Enzyme conjugates of antibodies support considerable amplification in imaging studies. Agonists may be superior to antagonists for in vivo mapping of the receptor distribution because the internalized cargo remains in the cells for some time (discussed by Bawolak et al. , 2012 ) .
